Fab-based bispecific antibody formats with robust biophysical properties and biological activity

mAbs

Volumn 7, Issue 3, 2015, Pages 470-482

  Wu, Xiufeng ^a   Sereno, Arlene J ^a   Huang, Flora ^a   Lewis, Steven M ^b   Lieu, Ricky L ^a   Weldon, Caroline ^a   Torres, Carina ^a   Fine, Cody ^a   Batt, Micheal A ^a   Fitchett, Jonathan R ^a   Glasebrook, Andrew L ^a   Kuhlman, Brian ^b,c   Demarest, Stephen J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bispecific antibody; Fab interface design; IgG Fab; T cell; Tandem Fab

Indexed keywords

CD3 ANTIGEN; CD69 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2 RECEPTOR ALPHA; PERTUZUMAB; TRASTUZUMAB; BISPECIFIC ANTIBODY; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BIOPHYSICS; CARCINOMA CELL; CELL PROLIFERATION; CIRCULAR DICHROISM; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; EXPRESSION VECTOR; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SIZE EXCLUSION CHROMATOGRAPHY; STOICHIOMETRY; STOMACH TUMOR; SURFACE PLASMON RESONANCE; T LYMPHOCYTE ACTIVATION; CHEMISTRY; GENETICS; IMMUNOLOGY; PROTEIN STABILITY; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; CELL LINE, TUMOR; HUMANS; PROTEIN STABILITY; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84945176688     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1022694     Document Type: Article

References (47)

1. Ellis LM, Hicklin DJ. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res 2009; 15: 7471-8; PMID: 20008847; http://dx. doi. org/10. 1158/1078-0432. CCR-09-1070.
2. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895-9; PMID: 18483355; http://dx. doi. org/10. 1158/1078-0432. CCR-07-2248.
3. Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer Cell 2002; 2: 99-102; PMID: 12204529.
4. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31: 621-32; PMID: 24094861; http://dx. doi. org/10. 1016/j. tibtech. 2013. 08. 007.
5. Demarest SJ, Hariharan K, Dong J. Emerging antibody combinations in oncology. MAbs 2011; 3: 338-51; PMID: 21697653; http://dx. doi. org/10. 4161/mabs. 3. 4. 16615.
6. Bird RE, Walker BW. Single chain antibody variable regions. Trends Biotechnol 1991; 9: 132-7; PMID: 1367550; http://dx. doi. org/10. 1016/0167-7799(91) 90044-I.
7. Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U S A 1993; 90: 7538-42; PMID: 8356052; http://dx. doi. org/10. 1073/pnas. 90. 16. 7538.
8. Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997; 15: 159-63; PMID: 9035142; http://dx. doi. org/10. 1038/nbt0297-159.
9. Perisic O, Webb PA, Holliger P, Winter G, Williams RL. Crystal structure of a diabody, a bivalent antibody fragment. Structure 1994; 2: 1217-26; PMID: 7704531; http://dx. doi. org/10. 1016/S0969-2126(94) 00123-5.
10. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009; 1: 539-47; PMID: 20073127; http://dx. doi. org/10. 4161/mabs. 1. 6. 10015.
11. Rothlisberger D, Honegger A, Pluckthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005; 347: 773-89; PMID: 15769469; http://dx. doi. org/10. 1016/j. jmb. 2005. 01. 053.
12. Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 2008; 11: 675-87; PMID: 18729019.
13. Mabry R, Snavely M. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles. IDrugs 2010; 13: 543-9; PMID: 20721825.
14. Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014; 32: 191-8; PMID: 24463572; http://dx. doi. org/10. 1038/nbt. 2797.
15. Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert, R, Lawrence, D, Sherwood, S, DeForge, L, et al. Design, construction, and in vitro analyses of multivalent antibodies. J Immunol 2003; 170: 4854-61; PMID: 12728922; http://dx. doi. org/10. 4049/jimmunol. 170. 9. 4854.
16. Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009; 393: 672-92; PMID: 19699208; http://dx. doi. org/10. 1016/j. jmb. 2009. 08. 032.
17. Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 2009; 1: 128-41; PMID: 20061822; http://dx. doi. org/10. 4161/mabs. 1. 2. 7631.
18. Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley, E, et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011; 286: 4703-17; PMID: 21123183; http://dx. doi. org/10. 1074/jbc. M110. 184317.
19. Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3: 273-88; PMID: 21393993; http://dx. doi. org/10. 4161/mabs. 3. 3. 15188.
20. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25: 1290-7; PMID: 17934452; http://dx. doi. org/10. 1038/nbt1345.
21. Jakob CG, Edalji R, Judge RA, DiGiammarino E, Li Y, Gu J, Ghayur T. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig) molecule. MAbs 2013; 5: 358-63; PMID: 23549062; http://dx. doi. org/10. 4161/mabs. 23977.
22. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64: 2343-6; PMID: 15059883; http://dx. doi. org/10. 1158/0008-5472. CAN-03-3856.
23. Wu X, Sereno AJ, Huang F, Zhang K, Batt M, Fitchett JR, He D, Rick HL, Conner EM, Demarest SJ. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. mAbs 2015; 7(2): 364-376; PMID: 25611120.
24. Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011; 11: 843-53; PMID: 21449821; http://dx. doi. org/10. 1517/14712598. 2011. 572874.
25. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69: 4941-4; PMID: 19509221; http://dx. doi. org/10. 1158/0008-5472. CAN-09-0547.
26. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, et al. Targeted therapy with the Tcell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-8; PMID: 21576633; http://dx. doi. org/10. 1200/JCO. 2010. 32. 7270.
27. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther 2012; 136: 334-42; PMID: 22940266; http://dx. doi. org/10. 1016/j. pharmthera. 2012. 07. 013.
28. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 2006; 12: 4441s-4445s; PMID: 16857825; http://dx. doi. org/10. 1158/1078-0432. CCR-06-0286.
29. Kuhlman B, Boice JA, Fairman R, Raleigh DP. Structure and stability of the N-terminal domain of the ribosomal protein L9: evidence for rapid two-state folding. Biochemistry 1998; 37: 1025-32; PMID: 9454593; http://dx. doi. org/10. 1021/bi972352x.
30. Mallender WD, Voss EW Jr. Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem 1994; 269: 199-206; PMID: 8276795.
31. Gruber M, Schodin BA, Wilson ER, Kranz DM. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol 1994; 152: 5368-74; PMID: 8189055.
32. Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, et al. Effector cell recruitment with novel Fv-based dualaffinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 2010; 399: 436-49; PMID: 20382161; http://dx. doi. org/10. 1016/j. jmb. 2010. 04. 001.
33. Wang L, He Y, Zhang G, Ma J, Liu C, He W, Wang W, Han H, Boruah BM, Gao B. Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody. PLoS One 2013; 8: e75589; PMID: 24086580; http://dx. doi. org/10. 1371/journal. pone. 0075589.
34. Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res 2014; 74: 5561-71; PMID: 25228655; http://dx. doi. org/10. 1158/0008-5472. CAN-13-3622-T.
35. Michalk I, Feldmann A, Koristka S, Arndt C, Cartellieri M, Ehninger A, Ehninger G, Bachmann MP. Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8. PLoS One 2014; 9: e95517; PMID: 24751697; http://dx. doi. org/10. 1371/journal. pone. 0095517.
36. Scheer JM, Sandoval W, Elliott JM, Shao L, Luis E, Lewin-Koh SC, Schaefer G, Vandlen R. Reorienting the Fab domains of trastuzumab results in potent HER2 activators. PLoS One 2012; 7: e51817; PMID: 23284778; http://dx. doi. org/10. 1371/journal. pone. 0051817.
37. Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Pluckthun A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure 2013; 21: 1979-91; PMID: 24095059; http://dx. doi. org/10. 1016/j. str. 2013. 08. 020.
38. Li B, Meng Y, Zheng L, Zhang X, Tong Q, Tan W, Hu S, Li H, Chen Y, Song J, et al. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. Cancer Res 2013; 73: 6471-83; PMID: 24046294; http://dx. doi. org/10. 1158/0008-5472. CAN-13-0657.
39. Wang JH, Reinherz EL. The structural basis of alphabeta T-lineage immune recognition: TCR docking topologies, mechanotransduction, and co-receptor function. Immunol Rev 2012; 250: 102-19; PMID: 23046125; http://dx. doi. org/10. 1111/j. 1600-065X. 2012. 01161. x.
40. Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, et al. Combined inhibition of tumor necrosis factor alpha and onterleukin-17 As a yherapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 2015; 67: 51-62; PMID: 25303306; http://dx. doi. org/10. 1002/art. 38896.
41. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108: 11187-92; PMID: 21690412; http://dx. doi. org/10. 1073/pnas. 1019002108.
42. Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem 2015; 290(12): 7535-7562.
43. Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. mAbs 2015; 7 (2): 377-389; PMID: 25621507.
44. Casimiro DR, Wright PE, Dyson HJ. PCR-based gene synthesis and protein NMR spectroscopy. Structure 1997; 5: 1407-12; PMID: 9384559; http://dx. doi. org/10. 1016/S0969-2126(97)00291-8.
45. Day ES, Capili AD, Borysenko CW, Zafari M, Whitty A. Determining the affinity and stoichiometry of interactions between unmodified proteins in solution using Biacore. Anal Biochem 2013; 440: 96-107; PMID: 23711722; http://dx. doi. org/10. 1016/j. ab. 2013. 05. 012.
46. Kim KS, Sun ZY, Wagner G, Reinherz EL. Heterodimeric CD3epsilongamma extracellular domain fragments: production, purification and structural analysis. J Mol Biol 2000; 302: 899-916; PMID: 10993731; http://dx. doi. org/10. 1006/jmbi. 2000. 4098.
47. Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 2007; 355: 751-7; PMID: 17321501; http://dx. doi. org/10. 1016/j. bbrc. 2007. 02. 042.